Characteristics Associated with COVID-19 Vaccine Hesitancy: A Nationwide Survey of 1000 Patients with Immune-mediated Inflammatory Diseases

Overview

Journal Vaccine

Specialty Allergy & Immunology

Date 2021 Oct 3

PMID 34600751

Citations 17

Authors

Rodrigo Poubel Vieira Rezende

Alessandra S Braz

Maria Fernanda B Guimaraes

Sandra Lucia E Ribeiro

Rejane Maria R Abreu Vieira

Blanca E Bica

Vitor A Cruz

Ketty Lysie Libardi Lira Machado

Joana S Carvalho

Odirlei A Monticielo

Lilian D Valadares

Katia Lino Baptista

Anna Carolina F M Gomes Tavares

Adriana M Kakehasi

Edgard T Neto

Ana Karla Guedes Melo

Gilda A Ferreira

Viviane A de Souza

Gecilmara S Pileggi

Marcelo M Pinheiro

Affiliations

Soon will be listed here.

Abstract

Objectives: To identify potential predictors of COVID-19 vaccine hesitancy (C19-VH) in adults with immune-mediated inflammatory diseases (IMID).

Methods: A total of 1000 IMID patients were enrolled in this web-based cross-sectional study. A standardised and self-administered survey was designed by members of the Brazilian Society of Rheumatology Steering Committee for Infectious and Endemic diseases and distributed to IMID patients spread across Brazil.

Results: Of the 908 (90.8%) respondents eligible for analysis, 744 (81.9%) were willing to get vaccinated against COVID-19. In our multivariable logistic regression model, concurrent malignancy, fibromyalgia, hydroxychloroquine use, and recent corticosteroid pulse therapy were independently associated with higher odds of C19-VH. The short duration of COVID-19 vaccine clinical trials was the main reason for C19-VH.

Conclusion: We identified novel characteristics potentially associated with C19-VH among adults with IMID. Greater awareness on the safety and efficacy of COVID-19 vaccines is needed for both IMID patients and attending physicians.

Citing Articles

A scoping review of COVID-19 vaccine hesitancy: refusal rate, associated factors, and strategies to reduce.

Bahreini R, Sardareh M, Arab-Zozani M Front Public Health. 2024; 12:1382849.

PMID: 39473604 PMC: 11518786. DOI: 10.3389/fpubh.2024.1382849.

Did We Overreact? Insights on COVID-19 Disease and Vaccination in a Large Cohort of Immune-Mediated Inflammatory Disease Patients during Sequential Phases of the Pandemic (The BELCOMID Study).

Geldof J, Truyens M, Sabino J, Ferrante M, Lambert J, Lapeere H Vaccines (Basel). 2024; 12(10).

PMID: 39460324 PMC: 11510991. DOI: 10.3390/vaccines12101157.

Global Comparison of COVID-19 Vaccination Rates among Psoriasis Patients.

Korouri E, Jeong C, Peterson H, Valenzuela F, Romiti R, Didaskalu J Life (Basel). 2024; 14(10).

PMID: 39459597 PMC: 11509075. DOI: 10.3390/life14101297.

Real-world data on tolerability of COVID-19 vaccination in patients with rheumatoid arthritis based on patient-reported outcomes.

Feuchtenberger M, Kovacs M, Eder A, Nigg A, Almanzar G, Prelog M Rheumatol Adv Pract. 2024; 8(4):rkae111.

PMID: 39282624 PMC: 11398971. DOI: 10.1093/rap/rkae111.

Safety of CoronaVac and ChAdOx1 vaccines against SARS-CoV-2 in patients with rheumatoid arthritis: data from the Brazilian multicentric study safer.

Cruz V, Guimaraes C, Rego J, Machado K, Miyamoto S, Burian A Adv Rheumatol. 2024; 64(1):58.

PMID: 39135131 DOI: 10.1186/s42358-024-00397-5.

References

Vieira de Rezende R, Mattos G, de Mello Leal Augusto R, Machado Gayer C, Mendes Klumb E . Predictors for seasonal influenza vaccination and reasons for inadequate vaccination coverage against a broad spectrum of vaccine-preventable diseases: a cross-sectional study among a Brazilian cohort of adult patients with systemic lupus.... Lupus. 2019; 28(6):794-796. DOI: 10.1177/0961203319846383. View

Priori R, Pellegrino G, Colafrancesco S, Alessandri C, Ceccarelli F, Di Franco M . SARS-CoV-2 vaccine hesitancy among patients with rheumatic and musculoskeletal diseases: a message for rheumatologists. Ann Rheum Dis. 2021; 80(7):953-954. DOI: 10.1136/annrheumdis-2021-220059. View

Campochiaro C, Trignani G, Tomelleri A, Cascinu S, Dagna L . Potential acceptance of COVID-19 vaccine in rheumatological patients: a monocentric comparative survey. Ann Rheum Dis. 2021; 80(6):816-817. DOI: 10.1136/annrheumdis-2020-219811. View

Anderson R, Vegvari C, Truscott J, Collyer B . Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination. Lancet. 2020; 396(10263):1614-1616. PMC: 7836302. DOI: 10.1016/S0140-6736(20)32318-7. View

MacDonald N . Vaccine hesitancy: Definition, scope and determinants. Vaccine. 2015; 33(34):4161-4. DOI: 10.1016/j.vaccine.2015.04.036. View

Furer V, Eviatar T, Zisman D, Peleg H, Paran D, Levartovsky D . Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis. 2021; 80(10):1330-1338. DOI: 10.1136/annrheumdis-2021-220647. View

Medeiros-Ribeiro A, Aikawa N, Saad C, Yuki E, Pedrosa T, Fusco S . Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial. Nat Med. 2021; 27(10):1744-1751. DOI: 10.1038/s41591-021-01469-5. View

Boekel L, Hooijberg F, van Kempen Z, Vogelzang E, Tas S, Killestein J . Perspective of patients with autoimmune diseases on COVID-19 vaccination. Lancet Rheumatol. 2021; 3(4):e241-e243. PMC: 7906725. DOI: 10.1016/S2665-9913(21)00037-0. View

Gianfrancesco M, Hyrich K, Al-Adely S, Carmona L, Danila M, Gossec L . Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020; 79(7):859-866. PMC: 7299648. DOI: 10.1136/annrheumdis-2020-217871. View

10.

Maltezou H, Pavli A, Dedoukou X, Georgakopoulou T, Raftopoulos V, Drositis I . Determinants of intention to get vaccinated against COVID-19 among healthcare personnel in hospitals in Greece. Infect Dis Health. 2021; 26(3):189-197. PMC: 8011642. DOI: 10.1016/j.idh.2021.03.002. View

11.

Felten R, Dubois M, Ugarte-Gil M, Chaudier A, Kawka L, Bergier H . Vaccination against COVID-19: Expectations and concerns of patients with autoimmune and rheumatic diseases. Lancet Rheumatol. 2021; 3(4):e243-e245. PMC: 7906671. DOI: 10.1016/S2665-9913(21)00039-4. View

12.

Lopes Marques C, Kakehasi A, Pinheiro M, Mota L, Albuquerque C, Rocha Silva C . High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19: first results of ReumaCoV Brasil registry. RMD Open. 2021; 7(1). PMC: 7844930. DOI: 10.1136/rmdopen-2020-001461. View

13.

Gautret P, Lagier J, Parola P, Hoang V, Meddeb L, Mailhe M . RETRACTED: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020; 56(1):105949. PMC: 7102549. DOI: 10.1016/j.ijantimicag.2020.105949. View

14.

Lazarus J, Ratzan S, Palayew A, Gostin L, Larson H, Rabin K . A global survey of potential acceptance of a COVID-19 vaccine. Nat Med. 2020; 27(2):225-228. PMC: 7573523. DOI: 10.1038/s41591-020-1124-9. View

15.

Curtis J, Johnson S, Anthony D, Arasaratnam R, Baden L, Bass A . American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 1. Arthritis Rheumatol. 2021; 73(7):1093-1107. PMC: 8250724. DOI: 10.1002/art.41734. View